2023-04-24 06:22:24 ET
- WuXi AppTec press release ( OTCPK:WUXAY ): Q1 GAAP EPS of RMB0.72.
- Revenue of RMB8.96B (+5.8% Y/Y).
For further details see:
WuXi AppTec GAAP EPS of RMB0.72, revenue of RMB8.96Bhome / stock / wuxay / wuxay news
2023-04-24 06:22:24 ET
For further details see:
WuXi AppTec GAAP EPS of RMB0.72, revenue of RMB8.96BMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Wuxi AppTec Co. Ltd. ADR Company Name:
WUXAY Stock Symbol:
Market:
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations PR Newswire Revenue Reached RMB7,982 Million ; Excluding COVID-19 Commercial Projects, Down 1.8% Net Profit Attributable to the Owners of the Company Reached...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time PR Newswire Revenue Up 2.5% Year-over-Year to RMB40,341 Million ; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributa...
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma PR Newswire AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. ...